Interestingly, methylation at NF-kB sites is related to FAS gene silencing [175]; given bortezomib’s inhibitory effect on the NF-kB pathway, this could be an important area for future research, especially considering its mixed success in phase III trials treating AML patients and limited data in MDS patients [148,149]. The gene discussed is NFKB1; the disease is acute myeloid leukemia.